Skip to main content

Table 3 Univariate analysis of local recurrence in patients with GCTBa treated with curettage from 2008 to 2010. (n = 158)

From: Clinical outcome of primary giant cell tumor of bone after curettage with or without perioperative denosumab in Japan: from a questionnaire for JCOG 1610 study

Clinical factors No. of local recurrence (%) Univariate analysis
p valueb
Site
 Extremity 29/151 (19.2%) p = 0.746
 Trunk 1/7 (14.3%)
Campanacci grade
 Grade I 1/16 (6.3%) p = 0.034
 Grade II 15/97 (15.5%)
 Grade III 14/45 (31.1%)
Pathological fracture at presentation
 Yes 5/26 (16.7%) p = 0.972
 No 25/132 (18.9%)
Do you use denosumab for this case now?
 Yes 15/83 (18.1%) p = 0.758
 No 15/75 (20.0%)
Embolization before surgery
 Yes 4/8 (50%) p = 0.022
 No 26/150 (17.3%)
  1. aGCTB, giant cell tumor of bone
  2. bChi-square test